

NŪROSENE™

CORPORATE PRESENTATION

~~Q1 2021~~ March 18 M A Y 20, 2021

A [preliminary final](#) prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in [each certain](#) of the provinces [of British Columbia, Alberta, Saskatchewan and Ontario and the Yukon](#) and territories of [Canada](#). A copy of the [preliminary final](#) prospectus, and any amendment, is required to be delivered with this document. [The preliminary prospectus is still subject to completion. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued.](#) This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the [preliminary final](#) prospectus, [the final prospectus](#) and any amendment for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.



General

Prospective investors should rely only on the information contained in the [preliminary final prospectus dated February²² May 18, 2021](#) (the “**prospectus**”). [The prospectus constitutes a public offering of securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities. No securities regulatory authority has expressed an opinion about such securities and it is an offence to claim otherwise.](#) This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in the prospectus. [A prospective investor is not entitled to rely on parts of the information contained in this presentation to the exclusion of others. Nurosene Inc. \(the “**Company**”\)](#) The Company and the Agents have not authorized anyone to provide prospective investors with additional or different information. [The Company and the Agents are not offering to sell the common shares of the Company in any jurisdiction where the offer or sale of such securities is not permitted.](#) Capitalized terms that are not defined in this presentation have the meanings ascribed to them in the prospectus.

For prospective purchasers outside Canada, neither the Company nor any of the Agents has done anything that would permit this offering or possession or distribution of the prospectus in any jurisdiction where action for that purpose is required, other than in Canada. Prospective investors are required to inform themselves about, and to observe any restrictions relating to, this offering and the possession or distribution of the prospectus.

There is no market through which the securities of the Company may be sold and investors may not be able to resell the securities purchased under the prospectus. This may affect the pricing of the these securities in the secondary market, the transparency and availability of trading prices, the liquidity of these securities, and the extent of issuer regulation. Investment in the common shares of the Company is highly speculative and involves significant risk due to various factors, including the nature and early stage of the Company's business, limited operating history, lack of revenue to date and future revenue uncertainty and additional capital requirements. An investment in the securities of the Company should only be made by persons who can afford the total loss of their investment. Investors should consider the “Risk Factors” in the prospectus and consult with their own legal, tax and financial advisors with respect to all such risks before making an investment.

The common shares of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or any United States state securities laws and, subject to registration under the U.S. Securities Act and applicable United States state securities laws or certain exemptions therefrom, may not be offered, sold, transferred, delivered or otherwise disposed of, directly or indirectly, within the United States.

None of the common shares of the Company have been approved or disapproved by the U.S. Securities and Exchange Commission, or any other securities commission or regulatory authority in the United States, nor have any of the foregoing authorities or any Canadian provincial or territorial securities regulator passed upon or endorsed the merits of the offering of the common shares of the Company nor have they approved this presentation or confirmed the accuracy or adequacy of the information contained in this presentation. Any representation to the contrary is a criminal offense.

Forward-Looking Information

Certain statements in this presentation constitute forward-looking statements within the meaning of applicable Canadian [and United States](#) securities legislation (collectively herein referred to as “forward-looking statements”), which can often be identified by words such as “will”, “may”, “estimate”, “expect”, “plan”, “project”, “intend”, “anticipate” and other words or phrases such as “we are working to”, indicating that the statements are forward-looking. [Specifically, this news release contains forward-looking statements relating to, but not limited to: ability to help users of the Company's products; future growth of the mobile health and supplements industry; demand for the Company's products; efficacy of the Company's products and research efforts; product launch timeline and future products; use and success of digital marketing strategies to promote products; the Company's ability to extract and use gathered or sourced data; the Company's planned milestones and timing of same; and use of proceeds from the Offering.](#) Such forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors, including, but not limited to, risk factors included in this presentation [and the prospectus](#), that could cause the actual results, performance or achievements of the Company or industry results to differ materially from any future results, performance or achievements implied by such forward-looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals; [whether the development and commercialization of Company can successful develop and commercialize products and future products and the efficacy thereof; the ability of our contract manufacturer to source raw materials; the ability of the Company to meet the milestones within the timelines provided; the ability to successfully execute and complete the Company's business objectives; the success of plans to market, sell and distribute products and technologies; the successful deployment and execution of a data-driven digital marketing strategy; the identification and successful partnership with third party research institutions; the likelihood of success of any research and development; competition; and reliance on the leadership team.](#) These factors should be considered carefully and readers are cautioned not to place undue reliance on forward-looking statements.

Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

Historical statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by the Company. Any graphs, tables or other information in this presentation demonstrating the historical performance of the Company or any other entity contained in this presentation are intended only to illustrate past performance of such entities and are not necessarily indicative of future results of the Company. No statement in this document is intended to be nor may be construed as a profit forecast.

An investment in the Company is speculative and involves substantial risk and is only suitable for investors that understand the potential consequences and are able to bear the risk of losing their entire investment. Investors should consider the “Risk Factors” in the prospectus and consult with their own legal, tax and financial advisors with respect to all such risks before making an investment.

The Company is in the early stage of development and has a limited operational history, making it difficult to accurately predict business operations. The Company has limited resources and may run out of capital prior to becoming profitable. The Company may fail and investors may lose their entire investment.

An investment in the Company may have tax consequences to the investor. The Company assumes no responsibility for the tax consequences of any investment. Investors should confer with their own tax advisors regarding an investment in the Company.

DISCLAIMER

Notice to U.S. Investors: This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons," as such term is defined in Regulation S under the U.S. Securities Act, unless an exemption from such registration is available.

Risk Factors

An investment in the Company's securities is speculative and is subject to a number of risks and uncertainties that should be considered by a prospective investor. Prospective investors should carefully consider the risk factors described under "Risk Factors" in the prospectus before purchasing securities of the Company.

WHO WE ARE



Daniel Gallucci
Neuroscientist
Co-Founder



OUR GOAL IS YOU TO HELP

Nurosene is built on the principles of

neuroscience to help implement healthy habits designed to align your mind, body, and brain a mental wellness company that currently offers two distinct solutions: a line of nutraceuticals, as well as a Mobile Application that helps users develop habits that are conducive to brain health through its curated content..

Our goal is to help our clients users by offering actionable and adaptable fundamental strategies to improve daily mental health and overall brain performance.

~~We're a team of visionary founders with a highly experienced management team~~



Ranj Bath

Chief Executive Officer
and Director

~~Ranj, CEO of Nurosene, Mr. Bath~~ is an inspirational leader with over 20 years of experience in various senior-level marketing and branding roles. Previously, as VP Corporate Strategy at Beats Music (the streaming service owned by the Beats Electronics division of Apple Inc.), he was instrumental in driving strategy, partnerships and revenue, working with the brand through a \$3Bn acquisition by Apple Inc.. Ranj is an avid investor and advisor across a number of health, wellness and technology companies, including being an early stage investor in companies such as Bulletproof 360 Inc. and Classpass ClassPass Inc. that has now reached over \$1Bn valuation.



Blake Sing

Chief Financial Officer

Mr. Sing has been the Chief Financial Officer and Corporate Secretary of the Company since February 1, 2021. Prior to his appointment as an officer of the Company, Mr. Sing provided consulting services for clients in regard to Financial Reporting, ERP implementation, reporting and control processes. Mr Sing was a Corporate Controller at WeedMD from June 2020 to December 2020, the VP Finance at Heritage Cannabis from December 2019 to March 2020, the Director of Finance for CannTrust Holdings Inc. from 2017 to 2019 and a manager at Ernst and Young LLP from 2013 to 2017. Mr. Sing received a Bachelor of Commerce from the University of Cape Town in 2010 and a CPA/CA Designation in 2017.



Daniel Gallucci

Chief Innovation Officer

Mr. Gallucci has been the Chief Innovation Officer of the Corporation since December 14, 2020. Mr. Gallucci was the founder and acted as Director of Rehabilitation and Performance for Flux Bionetworks from 2014 to present. Mr. Gallucci was the founder of DG2, a data driven rehabilitation company, from 2013 to present. He has a Bachelor in Exercise Science and a minor in Psychology from the University of Connecticut, Diplomat Osteopath Manual Practitioner (DOMP) from Sutherland Academy of Osteopathy. Additionally, he completed a clinical neuroscience program with specialities in Neurologic Performance, Traumatic Brain Injury, Vestibular Rehabilitation, Neurodevelopmental Rehabilitation and Neurochemistry from Carrick Institute of Graduate Studies.



We're supported by experts with extensive experience in technology, neuroscience, mental health, and capital markets



Daniel Gallucci
Director

Mr. Gallucci has been the Chief Innovation Officer of the Corporation since December 14, 2020. Mr. Gallucci was the founder and acted as Director of Rehabilitation and Performance for Flux Bionetworks from 2014 to present. Mr. Gallucci was the founder of DG2, a data driven rehabilitation company, from 2013 to present. He has a Bachelor in Exercise Science and a minor in Psychology from the University of Connecticut, Diplomate Osteopath Manual Practitioner (DOMP) from Sutherland Academy of Osteopathy. Additionally, he completed a clinical neuroscience program with specialities in Neurologic Performance, Traumatic Brain Injury, Vestibular Rehabilitation, Neurodevelopmental Rehabilitation and Neurochemistry from Carrick Institute of Graduate Studies.



Mark Smithyes
Director

Mr. Smithyes is the currently a life sciences consultant. He was previously the President of Labtician Thea Inc. and a Country Head of the Pharmaceutical Business Unit at Alcon Inc., a Novartis company. He is currently the Chair of Life Sciences Ontario and was previously a Director at Medtech Canada and New Circles Community Services. He has an MBA from Northwestern University – Kellogg School of Management and was a graduate from Western University with a Bachelor of Arts.



Ranj Bath
Director

Mr. Bath is an inspirational leader with over 20 years of experience in various senior-level marketing and branding roles. Previously, as VP Corporate Strategy at Beats Music (the streaming service owned by the Beats Electronics division of Apple Inc.), he was instrumental in driving strategy, partnerships and revenue, working with the brand through a \$3Bn acquisition by Apple Inc.. Ranj is an avid investor and advisor across a number of health, wellness and technology companies, including being an early stage investor in companies such as Bulletproof 360 Inc. and ClassPass Inc. that has now reached over \$1Bn valuation.



Sheetal Jaitly
Director

Mr. Jaitly is the founder and CEO of TribalScale, a software design and development company. He has been working in the tech sector for over 15 years. Mr. Jaitly was also a Director at Xtreme Labs from August 2010 until August 2015. Additionally, he is a Board Member for the Ontario Association of Food Banks and participates as a mentor at the Founder Institute and the DMZ at Ryerson University.



Kirstine Stewart
Director

Kirstine Stewart is internationally recognised for her groundbreaking work and leadership at the intersection of media and technology. at companies including Twitter Inc. After establishing Twitter's first Canada office (pre IPO), she went on to lead Twitter's Media team across North America, including Entertainment, News and Sports. Prior, Kirstine was the head of the Canadian Broadcasting Corp, Hallmark Entertainment and more. Kirstine is Corporation and all television, radio and online English services after a succession of global broadcasting executive roles at Hallmark Cards, Inc., Trio NewsWorld International and Alliance Atlantis Communications Inc. A supporter of tech entrepreneurship by establishing shows like Dragons' Den and formerly as an advisor with Ryerson's DMZ, Kirstine is a founding member of MaRS Coalition of Innovators Against Racism and currently sits on the CAMH Foundation Board. Kirstine is the author of bestselling business book "Our Turn" published by Random House.



Andrew Parks
Director

Mr. Parks is the current CEO and Director of Fountain Asset Corporation. He was previously a Portfolio Manager and Research Analyst/Trader for Forge First Asset Management. He is a Chartered Financial Analyst from the CFA Institute. He graduated from Wilfred Laurier University with an Honours Bachelor of Business Administration.

OUR FOCUS

Our ecosystem of integrated solutions is the cornerstone of our mental health strategy.

Nurosene has developed an ecosystem of actionable solutions that support building a healthier brain.



OUR PRODUCTS

We have developed a Mobile Application that gives our users access to practical habit-forming activities through our mobile application which works optimally with our and a line of proprietary nutraceuticals supplements.

PREDICTIVE HEALTHCARE

We are working to leverage machine learning and Artificial Intelligence to help better predict outcomes for our Mobile Application users in the future. We are utilizing actionable behavioral plan to analyze trends and patterns in user behavioural data to help provide generate insights and be able to act guide the development in a more preventative manner roadmap⁰⁵ of our Mobile Application.

ALTERNATIVE THERAPIES & RESEARCH



We will be utilizing advancements in alternative medicine through clinical research to identify new forms of therapy for mental health.

We are dedicating efforts into creating partnerships focused on conducting studies to validate and refine our product offering, including our supplements and Mobile Application.



THE PROBLEM

- **Mental, neurological and substance use disorders (MNS) are common, highly disabling, and associated with significant premature mortality.**

The human, social and economic toll imposed by lack of attention to MNS across the world is considerable.¹

10%

It is estimated that at least 10% of the world's population is affected, and that 20% of children and adolescents suffer from some type of mental disorder.¹

264_M

People are affected by depression. More women are affected than men and depression is one of the main causes of disability worldwide.¹

76-85%

People with mental disorders receive no treatment.²

¹ <https://www.worldbank.org/en/topic/mental-health>

² <https://www.who.int/news-room/fact-sheets/detail/mental-disorders>

OUR PRODUCTS

- Our goal is to support users to achieve balance in their everyday lives

NŪROSENE

- **Complementing the power of technology with supplements**

We have created a program that comprises our native mobile application and proprietary nutraceutical supplements. We believe that to see holistic benefits you need to pair supplements with the implementation of healthier habits.

Our mobile application acts as a “messenger” designed to stimulate or inhibit certain areas of the brain and body. Our nutraceuticals can be used to reinforce these messages. The way they do this is through restoring proper structure and function to cells and their environment.

While these tools can be used individually, they are optimized when paired together.





- **Mobile Health and Supplements are rapidly growing industries**

\$236_{BN}

The Mobile Health (mHealth) market size is projected to be worth \$236.0 Billion by 2026.¹

\$298_{BN}

The global dietary supplements market is expected to reach \$298.5 Billion by 2027.

Amid the COVID-19 crisis, the global market for dietary supplements was estimated at US\$170.4 Billion in 2020.²


¹ <https://www.grandviewresearch.com/press-release/global-mhealth-app-market>

² https://www.reportlinker.com/p05900383/Global-Dietary-Supplements-Industry.html?utm_source=GNW

OUR PRODUCTS

- Offering actionable and adaptable strategies to improve daily mental health and overall brain performance.

NŪROSENE



THE CORE OF THE PROGRAM OUR METHODOLOGY

Foundational ~~4 STRATEGIES X 4 TARGETS~~ Beliefs

We've built a 4x4™ model of human behavior, an evidence-based way of improving mental health and performance by aligning the body, brain, and mind.

To do this we have 4 therapeutic strategies, that target 4 different human structures:



4x4

4X4 Model

The methodology behind our products is based on the Company's philosophy of the 4x4 model, which focuses on encouraging actionable strategies to affect 4 fundamental lifestyles (movement, cognitive training, nutrition, and recovery) with solutions aimed to affect 4 parts of the human body (spinal cord, cerebral cortex, brain stem, and peripheral nerves).

4 FUNDAMENTALS X 4 TARGETS

OUR METHODOLOGY

NÜROSENE


4X4

- Movement 
- Brain 
- Nutrition 
- Recovery 



SPINAL CORD

- Movement 
- Brain 
- Nutrition 
- Recovery 




PERIPHERAL NERVE



CEREBRAL CORTEX

- Movement 
- Brain 
- Nutrition 
- Recovery 



BRAIN STEM

- Movement 
- Brain 
- Nutrition 
- Recovery 

MOBILE APPLICATION

We are developing a virtual care mobile application to provide continuous support to those suffering from mental health issues, driven from The Mobile Application was developed based on the principles of the Company's in-house methodology of the 4x4 model principles™ approach.

The Mobile Application will provide users with provides quick and efficient activities and behavior designed by our team, focused on each of the 4x4 suggestions within 4 primary areas; movement, the brain, recovery, and nutrition. The application will provide the framework for users to participate in activities developed by our team to support users to improve these aspects of their lives. We will provide programs, blogs and activities alongside to encourage further engagement with our users. model principles.

Our mobile application creates a high degree of personalization and optimizes for nature's greatest strength, adaptability, and is the foundation of all of the content driven through our Mobile Application.

We launched the Mobile Application on iOS and Android with no cost to the user in April 2021.



Examples of activities offered in the Mobile Application include: pursuit exercises, which require the user to follow an on-screen dot with their eyes; and gaze stabilization exercises, which require the user to focus on a dot while controlling their breathing. The activities are created with certain goals or outcomes in mind, or aim to provide certain benefits over time. For example, pursuits have been used by clinicians as a method of evaluating certain physical and behavioral disorders.

In addition to activities and supplement tracker, the Mobile Application also features blogs and a journal feature for the users.

PROPRIETARY NUTRACEUTICALS

We feel our best
when our cells enjoy a
harmonious structural
and functional
relationship, as
nature intended



- Our proprietary blends achieve this harmony by targeting specific structures and their inherent functions both inside and outside our cells
- Our nutraceuticals target the structure and function of over 500 biochemical processes in the human body

NUTRACEUTICAL PRODUCTS

The Company has developed two initial nutraceutical products, Nuro Drive and Nuro Restore, which will be available for purchase May 2021.



- Designed to help restore health by improving cellular structure and function and focusing on the interactions between cells in the body.
- The products were developed with an emphasis to help users feel their best and realize their potential.

NÜROSENE

TRACK YOUR PROGRESS

● The Mobile Application & Nutraceutical Supplements

The Mobile Application features a built-in supplement tracker that can allow users to track their supplement intake through the app. The supplement tracker allows the user to go into the app, select the supplement they intend to take (Nuro Drive or Nuro Restore), enter a start date for their supplement cycle, and then answer a series of questions to establish a baseline of their overall health.

The user will be prompted every cycle, approximately every 4 weeks, for continuous interactive check-ins, as long as the user is using the product.

The user is not required to take both supplements to use this feature. Users are required to manually provide the Mobile Application information about their nutraceutical consumption.



NÜROSENE

Product Launch Timeline

Early Q2 2021

Late Q3 2021



Designed and formulated, by to improve physical and cognitive energy levels. The mitochondria (energy producer of the cell) is a prominent cellular target along with a host of different structures. our Chief Innovation Officer Daniel Gallucci, targeted at improving energy levels

The formulation consists of 6 different B Vitamins alongside other ingredients, including K²-MK7, PQQ and COQ10. PQQ has been linked to potential health benefits such as improved energy utilization.¹



NURO RESTORE

Designed to improve sleep, reduce stress and pain and inflammation. The formulation includes our proprietary blend: L-Cysteine, Glycine, L-theanine, 5-HTP and Gaba. Other ingredients include zinc, two forms of magnesium, and Vitamin B6.

Designed and formulated, by our Chief Innovation Officer Daniel Gallucci, targeted at improving sleep, reducing stress, and pain and inflammation. The formulation includes our proprietary blend: L-Cysteine, Glycine, L-theanine, 5-HTP and Gaba. Other ingredients include zinc, two forms of magnesium, and Vitamin B6). Consumption of magnesium supplements has been linked to relieving various neurological disorders, such as anxiety and depression.²



FUTURE PRODUCTS

We are running continuous research and development using customer data and various research partnerships. We plan to introduce 3 additional nutraceutical products in the upcoming calendar year as well as commence researching other formulations. Our Chief Innovation Officer will focus efforts on research and the evolution of our product line.

The Company plans to introduce three (3) additional nutraceutical products in Q3 of the calendar year 2021. The Company will work with our contract manufacturer to source raw materials, and ensure quality assurance protocols are met.

1 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804159/>

2 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024559/>

• We plan to deploy data-driven digital marketing strategies to promote both our Mobile Application and our line of nutraceutical products, using a multi-layered and multi-channel approach, through:

- SOCIAL MEDIA
- SEARCH
- DISPLAY
- VIDEO
- MOBILE
- RE-MARKETING



Our product marketing program includes plans to engage in targeted advertising, influencer marketing and social media marketing.

Additionally, we will be driving our marketing campaigns through a variety of channels including targeted promotions and business development efforts focused on professional and collegiate sports teams, college faculties, elite performance training centers and personal health and fitness coaches.



ALTERNATIVE THERAPIES

Emphasize continued
research, innovation
and advancements **in
brain health.**

RESEARCH

- **As we dig deeper into mental health, it's critical that we stay at the leading edge of research and advancements in the sector**

We're dedicating efforts into partnerships focused on drug development and alternative therapies derived from novel molecules.


Advancing clinical research in alternative therapies and experiential therapies for mental health

Commercialize products that help patients find new forms of treatment

RESEARCH

- **Nurosene's business model emphasizes continued research, innovation and advancements in brain health.**

We are dedicating efforts into creating partnerships focused on conducting studies to validate and refine our product offering, including our supplements and Mobile Application.



NŪROSENE



● **PREDICTIVE HEALTHCARE**

Using a data-driven approach to better understand our future selves



Improved picture of an individual's mental health for today and for their future.



NÜROSENE

Better understand our users

The Company will utilize our user behaviour data gained from the users interaction with our Mobile Application to provide strategies and recommended solutions to our user base. As users continue to interact with the Mobile Application, the application will accumulate ongoing behavioural data from the user. We are enabling the ability to correlate passive and active data collected through application programming interfaces (APIs) to smartphones and wearables that will give us the utmost opportunity to find solutions and better understand the mental status of our users. Our in-house data scientist, utilizing machine learning, will determine patterning and provide an overall improved picture of an individual's mental health for today and for their future.



NÜROSENE

THE FUTURE OF DATA

PREDICTIVE HEALTHCARE

Be better prepared for tomorrow

Our next step is to have users integrate existing data using health-based applications and wearables. Coupled with our ability to track user behavior in our app, this will help us validate our digital phenotyping of mental health.

The ability to correlate passive and active data provided through smartphones and wearables will give us the utmost opportunity to find solutions and better understand the mental status of our users.


Our in-house data scientist, utilizing AI and machine learning, will continuously push the boundaries to determine patterning and provide an overall improved picture of an individual's mental health for today and for their future.

Help better predict outcomes

We will extract specific passive data points needed to help better predict outcomes as well as make suggestions for our users through the Mobile Application. Our Chief Innovation Officer will drive the initial data analysis outcomes in collaboration with our in-house data scientists' findings. With more users and data, the Company may seek partnerships with data analytics firms or with researchers to leverage our findings to improve developments in brain health, including through further development of the Mobile Application and/or nutraceuticals.



WHERE WE ARE GOING



NÜROSENE

MILESTONES



1. In the event the Company completes the Maximum Offering, the Company will allocate further funds to develop additional functionality and features for the Mobile Application.

COMPETITIVE LANDSCAPE


● **Uniquely Positioned**

● **Technology Driven**

● **Community Based**

● **Researched Centered**

● **Product Focused**



- **Competitors in this space are gaining huge momentum**

In accordance with Section 13.7(4) of National Instrument 41-101 – General Prospectus Requirements, all of the information relating to the Company’s comparables and any disclosure relating to the comparables, which is contained in the presentation to be provided to potential investors, has been removed from this template version for purposes of its filing on the System for Electronic Document Analysis and Retrieval (SEDAR).

USE OF PROCEEDS

The Company anticipates using the available funds for the following principal purposes:

Use of Proceeds	Estimated Expenditure (\$)
Estimated costs of the Offering ¹	\$400,000
Sales and marketing	\$2,000,000
Mobile application development and technology costs	\$2,054,000
Nutraceutical product development	\$500,000
Research projects and partnerships	\$500,000
General and administrative	\$1,065,000
Unallocated working capital	\$1,971,000

1. Includes the agent's expenses, legal, audit, regulatory, listing and printing fees.

The Company anticipates using the available funds for the following principal purposes:

Principal Purposes	Estimated Expenditure (Minimum Offering) (\$)	Estimated Expenditure (Maximum Offering) (\$)
Estimated costs of the Offering ¹	\$400,000	\$400,000
Mobile Application development	\$450,000	\$1,940,000
Nutraceutical product development	\$110,000	\$110,000
Manufacturing and Distribution	\$1,300,000	\$1,600,000
Sales and marketing	\$1,380,000	\$1,380,000
Research projects and partnerships	\$200,000	\$1,200,000
General and administrative	\$1,065,000	\$1,065,000
Payment of TribalScale	\$195,000	\$195,000
Available funds:	\$5,100,000	\$7,890,000

1. Includes the agent's expenses, legal, audit, regulatory, listing and printing fees.

	Outstanding after giving effect to the Offering	Outstanding after giving effect to exercise of full Agents' Over-Allotment Option ⁽¹⁾ (Unaudited)
Common Shares	31,863,745⁽²⁾⁽³⁾	33,197,078⁽²⁾⁽³⁾
Incentive Stock Options	1,635,000⁽⁴⁾	1,635,000⁽⁴⁾
Finder's Warrants	185,788	185,788
Agent's Options	622,222	715,555
Pro-Forma Fully Diluted	34,306,755	35,733,421

(1) The Agents' Over-Allotment Option allows the Agents to sell up to an additional 1,333,333 Additional Shares at the Offering Price for additional gross proceeds of up to \$1,200,000. The Agents' Over-Allotment Option is exercisable at the discretion of the Agents, in whole or in part, at any time and from time for a period of 60 days following the Closing Date.

(2) Includes the Corporate Finance Fee Shares in the amount of 55,555 and assumes the Agents' Fee is paid in cash.

(3) Includes 493,827 Common Shares to be issued to the TribalScale on the Closing Date.

(4) Includes 300,000 Options to be granted to Ranjit Bath, 150,000 Options to be granted to Blake Sing, 220,000 Options to be granted to directors who are not also executive officers and 665,000 Options to be granted to consultants of the Company, all at the Offering Price on the Listing Date. "Options and Other Rights to Purchase Securities".

	Outstanding after giving effect to the Minimum Offering	Outstanding after giving effect to the Maximum Offering	Outstanding after giving effect to exercise of full Agents' Over-Allotment Option ⁽¹⁾ (Unaudited)
Common Shares	28,530,412⁽²⁾⁽³⁾	31,863,745⁽²⁾⁽³⁾	33,197,078⁽²⁾⁽³⁾
Incentive Stock Options	1,635,000⁽⁴⁾	1,635,000⁽⁴⁾	1,635,000⁽⁴⁾
Finder's Warrants	185,788	185,788	185,788
Agent's Options	388,889	622,222	715,555
Pro-Forma Fully Diluted	30,740,089	34,306,755	35,733,421

(1) The Agents' Over-Allotment Option allows the Agents to sell up to an additional 1,333,333 Additional Shares at the Offering Price for additional gross proceeds of up to \$1,200,000. The Agents' Over-Allotment Option is exercisable at the discretion of the Agents, in whole or in part, at any time and from time for a period of 60 days following the Closing Date.

(2) Includes the Corporate Finance Fee Shares in the amount of 55,555 and assumes the Agents' Fee is paid in cash.

(3) Includes 493,827 Common Shares to be issued to the TribalScale on the Closing Date.

(4) Includes 300,000 Options to be granted to Ranjit Bath, 150,000 Options to be granted to Blake Sing, 220,000 Options to be granted to directors who are not also executive officers and 665,000 Options to be granted to consultants of the Company, all at the Offering Price on the Listing Date. See also "Options and Other Rights to Purchase Securities" in the prospectus.

Why Nurosene, Why Now?

Nurosene is built on the principles of neuroscience. We are taking a holistic approach to mental healthcare with our proprietary program. Our supplements blends are uniquely designed to target specific cell structures, functions, and biochemical processes.

Our predictive healthcare model was established to leverage the power of data to implement preventative measures to help our users live a better, healthier future.

We will be at the leading edge of critical research into alternative therapies and medicines to support advancements in the sector.

NŪROSENE™



Thank You

Investor Relations:
investors@nurosene.com



NŪROSENE

Thank You

Investor Relations:
investors@nurosene.com